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Abstract
Background: Primary eosinophlia associated with the FIP1L1-PDGFRA rearrangement represents
a subset of chronic eosinophilic leukaemia (CEL) and affected patients are very sensitive to imatinib
treatment. This study was undertaken in order to examine the prevalence and the associated
clinicopathologic and genetic features of FIP1L1-PDGFRA rearrangement in a cohort of 15 adult
patients presenting with profound eosinophilia (> 1.5 × 109/L).
Methods: Reverse transcriptase-polymerase chain reaction (RT-PCR) was used for the detection
of FIP1L1-PDGFRA rearrangement and the results confirmed by direct sequencing. C-KIT-D816V
mutation was analysed retrospectively by PCR and restriction-fragment-length-polymorphism
(PCR-RFLP), in all cases with primary eosinophilia.
Results: Two male patients with splenomegaly carried the FIP1L1-PDGFRA rearrangement, whilst
2 others were ultimately classified as suffering from idiopathic hypereosinophlic syndrome (HES)
and one from systemic mastocytosis. These patients were negative for the C-KIT-D816V mutation
and received imatinib (100–400 mg daily). Patients with CEL and HES responded to imatinib and
remained in complete haematological, clinical and molecular (for carriers of FIP1L1-PDGFRA
rearrangement) remission for a median of 28.2 months (range: 11–54), whilst the patient with
systemic mastocytosis did not respond. Interestingly, in both patients with FIP1L1-PDGFRA
rearrangement, the breakpoints into PDGFRA were located within exon 12 and fused with exons 8
and 8a of FIP1L1, respectively.
Conclusion: An early diagnosis of FIPIL1-PDGFRA-positive CEL and imatinib treatment offer to the
affected patients an excellent clinical therapeutic result, avoiding undesirable morbidity. Moreover,
although the molecular mechanisms underlying disease pathogenesis remain to be determined,
imatinib can be effective in patients with idiopathic HES.
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Background
Eosinophilia (> 0.5 × 109/L) is a common clinical finding
that can be secondary to a large variety of diseases. When
evaluation of eosinophilia fails to reveal an underlying
disease, the diagnosis of hypereosinophilic syndrome
(HES) is evocated. HES is defined by (1) eosinophilia (>
1.5 × 109/L) for more than 6 months; (2) exclusion of
reactive eosinophilia caused by parasitic infections, aller-
gies, or other known causes, as well as eosinophilia asso-
ciated with neoplasias; and (3) evidence of end-organ
damage [1-4]. Over the last decade, great progress has
been made in understanding the molecular basis of HES
that has resulted in the characterization of specific genetic
alterations linked to clonal eosinophilia. The most fre-
quent genetic aberration is the cryptic deletion of 4q12,
i.e. del(4)(q12), producing the FIP1-like 1/platelet-
derived growth factor receptor alfa (FIP1L1-PDGFRA)
fusion transcript, which results in an eosinophilic, myelo-
proliferative disorder (chronic eosinophilic leukaemia,
CEL) [5]. In addition, in a subset of patients with HES,
eosinophilia is secondary to a primitive Th2 lymphoid
disorder, overproducing interleukin-5 (IL-5), indicating
the existence of lymphocyte-mediated HES [3].
The FIP1L1-PDGFRA fusion gene induces increased tyro-
sine kinase activity of PDGFRA [5,6], and is present in
approximately 10–15% of patients with HES [5,7,8].
Despite the fact that these patients appear to have a more
severe disease phenotype, involving extensive end-organ
pathology [5,8-11], they are dramatically sensitive to
treatment with the tyrosine kinase inhibitor imatinib [5,8-
13]. Thus, early detection of FIPIL1-PDGFRA rearrange-
ment and the subsequent imatinib administration can
offer to the affected patients an excellent clinical therapeu-
tic outcome, avoiding undesirable morbidity and mortal-
ity.
This study was undertaken in order to examine both the
prevalence and the associated clinicopathologic and
genetic features of FIP1L1-PDGFRA  rearrangement in a
cohort of 15 adult patients presenting with eosinophilia
and an absolute eosinophil count higher than 1.5 × 109/L.
Methods
Patients
Peripheral blood (PB) and/or bone marrow (BM) from 15
patients (male/female: 7/8, mean age: 45.2 years, range:
22–72 years) with eosinophilia (eosinophils > 1.5 × 109/
L), without an unambiguous history of allergic diseases,
were referred to the Immunology Lab and examined for
the presence of FIP1L1-PDGFRA rearrangement. Regard-
less of the molecular analysis, a complete clinical and lab-
oratory examination was also performed. The diagnosis of
idiopathic HES, systemic mastocytosis and/or CEL was
based either on standard diagnostic criteria [1-3] or on the
result of the molecular analysis. Cytogenetic analysis was
performed in all, but one, patients with primary eosi-
nophilia and in two patients, for which ultimately
another diagnosis was made. Flow cytometric analysis for
the demonstration of CD3-CD4+ or CD3+CD4-CD8-
clones, implicated in lymphocyte-mediated HES, was per-
formed in all patients, but serum vitamin B12, IL-5 and
mast cell tryptase levels were not assayed. Detection of C-
KIT-D816V mutation was performed retrospectively in all
cases with primary eosinophilia.
Written informed consent was obtained from all patients
and the study was approved by the Institutional Review
Board of both hospitals (University Hospital of Larissa
and Papageorgiou General Hospital, Greece).
Molecular analyses
Detection of FIP1L1-PDGFRA fusion
The  FIP1L1-PDGFRA  rearrangement was analyzed by a
modified nested reverse transcriptase-polymerase chain
reaction (RT-PCR) protocol [14]. In particular, RNA was
extracted from BM or PB, and cDNA was reversed tran-
scribed, as previously described [15]. One sixth of the syn-
thesized cDNA was used in a first PCR reaction of 30 μL,
using 62.5 μM of each deoxynucleoside triphosphate, 20
pmol of each primer (sense: 5'-ACCTGGTGCTGATCTT-
TCTGAT-3' and antisense: 5'-TGAGAGCTTGTTTTTCACT-
GGA-3'), 1.6 mM MgCl2 and 1.4 μL of Taq Elongase
(Invitrogen, UK) in a PCR buffer supplied by the manu-
facturer. Thereafter, 1 uL of the first PCR product was used
as template for the nested PCR reaction (30 uL), along
with 62.5 μM of each deoxynucleoside triphosphate, 10
pmol of each primer (sense: 5'-AAAGAGGATACGAAT-
GGGACTTG-3' and antisense: 5'-GGGACCGGCTTAATC-
CATAG-3'), 1.5 mM MgCl2 and 0.5 U of Taq Polymerase
(Invitrogen, UK) in a PCR buffer supplied by the manu-
facturer. The primary PCR conditions were: 2 min at 94°C
followed by 32 cycles (94°C for 45 sec, 56°C for 45 sec,
68°C for 75 sec) followed by 5 min at 68°C. The condi-
tions for the nested PCR were: 2 min at 94°C followed by
25 cycles (94°C for 30 sec, 60°C for 30 sec, 72°C for 60
sec) followed by 5 min at 72°C after the last cycle. All PCR
amplifications were carried out in the PCR-engine appara-
tus PTC-200, MJ Research (Watertown-Mass., USA). The
first and nested PCR products were analyzed in 2.5% TBE
agarose gels. The cell line EOL-1 (with known FIP1L1-
PDGFRA rearrangement) served as positive control in our
experiments.
For the confirmation of nested PCR results, PCR products
with suspected FIP1L1-PDGFRA rearrangement were puri-
fied by QIAquick gel extraction kit (Qiagen, UK) and
directed sequenced using an ABI Prism 310 Genetic Ana-
lyzer (Applied Biosystems, Foster City, CA) and a Big Dye
Terminator DNA sequencing kit (Applied Biosystems).BMC Blood Disorders 2009, 9:1 http://www.biomedcentral.com/1471-2326/9/1
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Mutational analysis of C-KIT
The C-KIT-D816V mutation was analysed at the genomic
DNA level. In particular, DNA was extracted using the
QIAamp DNA Blood Mini kit (Qiagen, UK), according to
the manufacturer's instructions. Semi-nested PCR was
performed, as previously described [16], with some mod-
ifications. In particular, the first PCR was performed in a
final volume of 30 μL containing 100 uM of each dNTP,
1.5 mM MgCl2, and 0.5 U Taq polymerase (Invitrogen,
UK), and 10 pmol of each primer (sense: 5'-CACAGA-
GACTTGGCAGCCAG-3' and antisense: 5'-CAGGATTTA-
CATTATGAAAGTCACGG-3'). Aliquots of 1 μL of the PCR
product served as template for the semi-nested PCR, using
the same concentrations as above. The primers for the
nested PCR were: sense 5'-ATCCTCCTTACTCATGGTCG-
GATC-3' and the same antisense used for the primary
PCR. Each PCR cycle consisted of 30 seconds denaturation
at 94°C, 30 sec annealing at 56°C, and 45 sec extension
at 72°C. The first cycle was preceded by two minutes
denaturation at 94°C. The last cycle was extended by a five
minute elongation at 72°C. The first PCR run for 30 cycles
and nested-PCR for 25 cycles. All PCR amplifications were
carried out in the PCR-engine apparatus PTC-200, MJ
Research (Watertown-Mass., USA).
To detect the presence of the C-KIT-D816V mutation, the
semi-nested PCR products were digested with the endonu-
clease HinfI (New England Biolabs, USA) and the restric-
tion products were analysed by electrophoresis on a 4%
agarose TBE gels. The C-KIT-D816V mutation creates a
second restriction site within the semi-nested PCR prod-
ucts. The predicted sizes for the wild-type sequence were
121 bp and 68 bp, and for the mutated sequence 121 bp,
68 bp, 54 bp, and 14 bp [16].
Results
Amongst the 15 patients with eosinophilia, only two were
positive for the FIP1L1-PDGFRA rearrangement (13,3%).
Two others were classified as idiopathic HES and another
as systemic mastocytosis, after bone marrow and lymph
node biopsies, indicating mast cell infiltration. A sum-
mary of the clinical and laboratory findings for these
patients is presented in Table 1.
Within the remaining patients, one suffered from eosi-
nophilic gastroenteritis, two from asthma (all responded
to steroids), two from atypical myeloproliferative syn-
drome (one was also positive to JAK2-V617F mutation
and both responded to hydroxyurea therapy), one from
dermatomyocytis, one from bronchiectasis, and one from
chronic idiopathic urticaria. In two cases, the eosinophilia
was not permanent and ascribed to possible allergic
causes (also responded to steroids). Notably, only the
patient with eosinophilic gastroenteritis displayed eosi-
nophilia for more than 6 months.
All patients with primary eosinophilia (CEL, HES and sys-
temic mastocytosis) were negative for the C-KIT-D816V
Table 1: Clinical and laboratory findings of the patients with primary eosinophilia





















20.4/11.4 12.5 210 - 400 mg (I)
100 mg (M)
35 mo CHR, clinical, 
molecular 
remission
2 CEL M 22 Splenomegaly 27.0/10.2 13.1 157 - 100 mg (I)
100 mg (M)
11 mo CHR, clinical, 
molecular 
remission
3I d i o p a t h i c  
HES
M 23 Abdominal pain, 
lymphadeno-pathy, 
fatigue, cough





4I d i o p a t h i c  
HES
M 38 Cough, asthma 21.9/14.0 14.8 268 - 400 mg (I)
400 mg (M)
13 mo CHR
5 SM-Eo F 37 Malaise, arthralgia, 
gastritis, 
splenomagaly
13.8/5.5 12.7 673 IFN-a
for 2 y
400 mg 12 mo No response
Abbreviations: CEL, chronic eosinophilic leukaemia; HES, hypereosinophilic syndrome; SM-Eo, systemic mastocytosis with eosinophilia; M, male; F, 
female; WBC, white blood cell count; Hb, haemoglobin; PLT, platelets; I, induction therapy; M, maintenance therapy; CHR, complete haematological 
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mutation, while cytogenetic analysis in all, but one
patient (case 2 of Table 1), due to dry-tap on bone marrow
aspiration, was normal. Moreover, a clonal interleukin-5-
producing T-cell population was not detected by flow
cytometry in any of the above patients.
All patients with primary eosinophilia negative for the
FIP1L1-PDGFRA  rearrangement, displayed eosinophilia
for more than 6 months (mean: 7 months, range: 6–8).
Amongst them, one with idiopathic HES was receiving
imatinib as first line therapy and the others were receiving
imatinib after failure of their previous treatment (Table
1). The patients with idiopathic HES responded to imat-
inib in a dosage of 400 mg per day, displaying CHR and
clinical remission, and continue on imatinib, till now
(Table 1). The last patient, suffering from systemic masto-
cytosis with eosinophilia, was negative to FIP1L1-PDG-
FRA  rearrangement, as well as to the C-KIT-D816V
mutation, but did not respond to imatinib treatment.
Interestingly, she had initially received IFN-alfa subcuta-
neously for 2 years, with no response, and then received
imatinib (400 mg per day), for which she was also not
sensitive.
Considering the patients carrying the FIP1L1-PDGFRA
rearrangement, they were males, exhibiting splenom-
agaly. Both patients displayed more than one isoforms of
the fusion gene (Figure 1), similar to the majority of the
affected patients, as described in the literature. The RT-
PCR results were confirmed in both cases by sequencing
analysis. Interestingly enough, as for all patients reported
in the literature, the breakpoint into the PDGFRA gene
was located in exon 12 (different for each patient), that
was fused with exon 8 of the FIP1L1 gene for the first
patient and exon 8a for the second (Figure 1). Moreover,
the connection site between the genes was the same for
the isoforms of each patient, and their different length
was due to deletions in the FIP1L1 gene (for example in
case 1 of Table 1, one isoform was characterized by dele-
tion of the whole exon 7a of the FIP1L1 gene).
A more detailed clinical and laboratory presentation of
patients carrying the FIP1L1-PDGFRA  rearrangement is
presented below:
Case 1
The first patient presented maculo-papular rash on lower
extremities and abdomen and an absolute eosinophil
count of 2 × 109/L, one and half year before admission to
the hospital. Initially the rash was considered to be of
allergic etiology and the patient received local corticoster-
oids by a dermatologist. Nevertheless, a progressive dete-
rioration of the rash was observed, and the patient also
complained of fatigue and muscle weakness accompanied
by hypaesthesia of the peripheral parts of the lower
extremities that led to the weakness of walk, one week
prior to admission. At that time, the laboratory tests
showed that the eosinophils increased to 11.4 × 109/L and
moreover, a mild anaemia (Hb: 12.5 gr/dl) was present.
Clinical examination revealed splenomegaly (palpable
spleen 8 cm below the left costal margin), vesicular exan-
thema on the abdomen and the low extremities and
absent deep tendon reflexes. Bone marrow aspiration and
biopsy revealed an extensive eosinophil infiltration
(68%), whilst the cytogenetic analysis was normal. Molec-
ular analysis excluded the presence of BCR-ABL transcript,
while a FIP1L1-PDGFRA rearrangement was documented
(Figure 1A). Imatinib was initiated at a dosage of 400 mg
and after 14 days of treatment, the eosinophil count sig-
nificantly declined along with a dramatic reduction of
splenomegaly. Imatinib was well tolerated with an initial
decrease of Hb levels to 9 gr/dl, that was resolved by
reducing the imatinib dosage to 200 mg per day and
administrating 150 mcg of darbepoetin alfa, twice weekly
subcutaneously. The mobility and the hypaesthesia were
recovered 2 months later and PB and BM molecular signal
of the FIP1L1-PDGFRA fusion gene were undetectable 4
months after treatment. Six months later, the imatinib
dosage further declined to 100 mg per day, and the patient
is currently followed-up as an outpatient.
Case 2
The second patient displayed eosinophilia (10.2 × 109/L)
and mild anaemia (Hb: 13.1 gr/dl) during a routine labo-
ratory examination. A clinical examination revealed only
splenomegaly (palpable spleen 2 cm below the left costal
margin). Bone marrow aspiration was dry-tap, and for this
reason cytogenetic analysis was not performed. However
bone marrow biopsy revealed an extensive infiltration
(80%) by eosinophils. Molecular analysis revealed the
presence of the FIP1L1-PDGFRA rearrangement. Imatinib
was started at a dosage of 100 mg two weeks after the esti-
mation of eosinophilia and after 14 days of treatment, the
eosinophil count become normal (0.3 × 109/L) and the
spleen was not palpable below the left costal margin.
Imatinib was well tolerated without side effects, and PB
and BM molecular signal of the FIP1L1-PDGFRA fusion
gene was undetectable 3 months after treatment.
Discussion
In this study we describe our experience for the diagnostic
utility of the detection of FIP1L1-PDGFRA rearrangement
in patients with profound eosinophilia. In our cohort, the
prevalence of FIP1L1-PDGFRA rearrangement was 13.3%
in the total analysed group and 40% among patients with
primary eosinophilia. Till now, the recorded proportion
of  FIP1L1-PDGFRA-positive cases among such patients
varies widely, ranging from 0% to 56%, probably reflect-
ing small sample sizes, as in our cohort, and variable
inclusion criteria [5,7-13,17]. In the study, with the largestBMC Blood Disorders 2009, 9:1 http://www.biomedcentral.com/1471-2326/9/1
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cohort, Pardanani and co-workers screened 741 patients
with moderate to severe eosinophilia and reported a 3%
prevalence of FIP1L1-PDGFRA  fusion positivity [12].
Moreover, Klion also noted that 10%–50% of patients
meeting the classic definition of HES may be FIP1L1-PDG-
FRA-positive [18]. It is obvious, that a subsequent meta-
analysis, taking into account all published studies, could
clarify the true prevalence of FIP1L1-PDGFRA rearrange-
ment in patients with idiopathic eosinophilia and HES.
The detection of FIP1L1-PDGFRA rearrangement in the
second patient, directly after the estimation of eosi-
nophilia, resulted in the early diagnosis of CEL, with a
profound impact on the patient's clinical course and out-
come. Thus, it is not unreasonable to speculate that the
usage of molecular techniques for the early diagnosis of
suspected FIP1L1-PDGFRA-positive leukemias, can mod-
ify the diagnostic criteria of hypereosinophilic syndrome
with significant impact in undesirable morbidity and
mortality.
Interestingly, in both patients with FIP1L1-PDGFRA rear-
rangement, the breakpoints into PDGFRA were located in
exon 12 and fused with exons 8 and 8a of FIP1L1, respec-
tively. Till now, all described breakpoints occurred in an
FIP1L1 intron (spread from 7 to 10 at genomic DNA level)
and in exon 12 of PDGFRA [5,9]. Although in all reported
cases, the PDGFRA breakpoints were variable, they were
limited to exon 12 and more specifically within the region
encoding a WW-like domain [2]. A similar finding was
also observed in our patients (Figure 1). There is strong
evidence that the result of FIP1L1-PDGFRA rearrangement
is an interrupted PDGFRA juxtamembrane region, due to
an interstitial deletion of a tryptophan (W) residue of the
putative WW-domain (Figure 1). This domain is believed
to be a negative regulator of kinase activity and serves as
an auto-inhibitory domain. Thus, the interruption of the
juxtamembrane region of PDGFRA may serve as the pri-
mary mode of constitutive kinase activation and the
leukemic transformation of the affected cells [2,19].
In our study, both patients with FIP1L1-PDGFRA  rear-
rangement were male and exhibited splenomegaly, simi-
lar to the majority of the positive patients reported in the
literature. It is noteworthy that one patient displayed rash
as a presenting sign, considering that skin involvement is
rare in CEL [11,20]. Moreover, this patient displayed
undesirable morbidity due to initial misdiagnosis, while
the second one was diagnosed early after the demonstra-
tion of eosinophilia in routine laboratory examination,
without reference to the diagnostic criteria of HES [2-4].
This point should be highlighted, considering that even in
such patients, cardiac damage can be irreversible. On the
other hand, 2 HES patients were also sensitive to imatinib
treatment, and remained in CHR, receiving imatinib 9
and 50 months, respectively, after diagnosis. It has been
reported that up to 40% of imatinib responding patients
lack the FIP1L1-PDGFRA fusion [5,11,17,20], suggesting
the activation of other, still unknown, tyrosine kinases
that may contribute to disease pathogenesis and pheno-
Molecular analyses of patients with FIP1L1-PDFGRA rear- rangement Figure 1
Molecular analyses of patients with FIP1L1-PDFGRA 
rearrangement. A. Reverse transcriptase-polymerase 
chain reaction (RT-PCR) analysis of the FIP1L1-PDFGRA fusion 
gene isolated from bone marrow and peripheral blood of 
patients with chronic eosinophilic leukaemia at diagnosis. M: 
100 bp ladder molecular weight marker (Invitrogen, UK); 
Lane 1: case 1; Lane 2: case 2; Lane 3: cell line EOL-1 (posi-
tive control), Lane 4: negative PCR control (blank). It is note-
worthy that both patients, as well as the cell line EOL-1 
(positive control), display more than one mRNA isoforms of 
the fusion gene. B. Sequence variants for each patient with 
the fusion gene. FIP1L1 sequences are shown in lowercase 
and in blue, and PDGFRA sequences are shown in uppercase 
and in black. Exon numbering in FIP1L1 is based on a comple-
mentary DNA (cDNA) clone (GenBank accession number 
NM_030917). The amino acid sequence of the chimeric pro-
tein in site of fusion is indicated in green. C. Schematic repre-
sentation of the FIP1L1-PDGFRA fusion protein. In both 
cases the breakpoints in PDGFRA are located within the jux-
tamembrane region, between the two tryptophan (W) resi-
dues of the putative WW-domain.BMC Blood Disorders 2009, 9:1 http://www.biomedcentral.com/1471-2326/9/1
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type. Although in a recent report, Baccarani and coworkers
reported that such patients need higher doses of imatinib
and usually relapse [11], this does not appear to be abso-
lutely the rule [5,17], since in our cohort 2 HES patients
remain in CHR and clinical remission, receiving 100 and
400 mg of imatinib, respectively, as maintenance treat-
ment.
Moreover, we treated another patient with primary eosi-
nophilia, whose diagnosis was ultimately systemic masto-
cytosis. Regardless of the presence or absence of FIP1L1-
PDGFRA or C-KIT-D816V, patients with SM may present
with eosinophilia [21]. It is well documented today that
some of these patients carry the FIP1L1-PDGFRA  rear-
rangement and are sensitive to imatinib treatment, sug-
gesting that the molecular pathogenesis for this subset of
patients is similar to that of CEL [14,21]. Indeed, it has
been recently proposed that these patients should be
appropriately classified as systemic mastocytosis-CEL
[21]. However, our patient was negative for the FIP1L1-
PDGFRA rearrangement, as well as for the C-KIT-D816V
mutation, and did not respond to imatinib treatment.
Conclusion
An early diagnosis of FIP1L1-PDGFRA-positive CEL and
imatinib treatment can offer to affected patients an excel-
lent clinical therapeutic result, avoiding undesirable mor-
bidity and mortality. Moreover, although the molecular
mechanisms underlying disease pathogenesis and pheno-
type remain to be determined, imatinib can also be effec-
tive in patients with idiopathic HES.
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